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Abstract
Reactive oxygen species exert important functions in regulating several cellular signalling pathways. However, an excessive
accumulation of reactive oxygen species can perturb the redox homeostasis leading to oxidative stress, a condition which
has been associated to many neurodegenerative disorders. Accordingly, alterations in the redox state of cells and
mitochondrial homeostasis are established hallmarks in both familial and sporadic Parkinson’s disease cases. PINK1 and
Parkin are two genes which account for a large fraction of autosomal recessive early-onset forms of Parkinson’s disease and
are now firmly associated to both mitochondria and redox homeostasis. In this study we explored the hypothesis that super-
oxide anions participate in the generation of the Parkin and PINK1 associated phenotypic effect by testing the capacity of en-
dogenous and exogenous superoxide dismutating molecules to rescue the toxic effects induced by loss of PINK1 or Parkin, in
both cellular and fly models. Our results demonstrate the positive effect of an increased level of superoxide dismutase pro-
teins on the pathological phenotypes, both in vitro and in vivo. A more pronounced effectiveness for mitochondrial SOD2
activity points to the superoxide radicals generated in the mitochondrial matrix as the prime suspect in the definition of the
observed phenotypes. Moreover, we also demonstrate the efficacy of a SOD-mimetic compound, M40403, to partially amelio-
rate PINK1/Parkin phenotypes in vitro and in vivo. These results support the further exploration of SOD-mimetic compounds as
a therapeutic strategy against Parkinson’s disease.
Introduction
Parkinson’s disease (PD) is a neurodegenerative motor disorder
associated with the preferential death of dopaminergic neurons
in the Substantia Nigra pars compacta. Even though the etiology of
this disease, which includes environmental and genetic causes,
is still not completely elucidated, oxidative stress and mito-
chondrial dysfunction have been identified as major factors in-
volved in the pathogenesis of PD. In fact, alterations in the
redox cellular state and mitochondrial homeostasis are com-
mon hallmarks in both familial and sporadic PD cases (1).
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Mitochondria are dynamic organelles, organized in an inter-
connected network, with the ability to fuse and divide. The fusion
and fission pathways are implicated in homeostatic maintenance
of mitochondrial DNA stability and respiratory function, as well as
influencing apoptosis (2). As a consequence, the process known as
mitochondrial quality control, which refers to mitophagy, organ-
elle fission, fusion and subcellular translocation, is essential for
mitochondria performance. The malfunctioning of mitochondrial
dynamics results in the accumulation of defective organelles,
leading to oxidative stress and cell death (3). On the other hand,
even oxidative stress can affect mitochondrial morphology and
functions. Accordingly, a growing body of evidence suggests that
redox cellular state and mitochondrial homeostasis are tightly in-
terconnected and that alterations in reactive oxygen species (ROS)
levels go in parallel with changes in mitochondrial dynamics (3).
Mutations and deletions in the genes Parkin and PINK1, ac-
counting for the majority of autosomal recessive early-onset
forms of PD (4), have been demonstrated to affect both mito-
chondrial and redox homeostasis (5). Remarkably, the first defi-
nition of the function played by the proteins encoded by these
genes at the mitochondrial level came from studies carried out
in Pink1 and parkin knockout Drosophila models (reviewed in (6)).
In addition to mitochondria alterations, PINK1 or Parkin defi-
ciency has also been reported to be associated with ROS produc-
tion and/or increased susceptibility to oxidative conditions:
Pink1 deficient flies show increased sensitivity to multiple in-
sults including oxidative stress (7), while parkin mutant flies are
characterized by an alteration in oxidative stress response (8)
and an increased sensitivity to oxygen radical injury (9). With the
exception of muscular defects, phenotypes similar to those firstly
described in Drosophila were subsequently described in other
PINK1 and parkin knock-out cellular and animal models (10–15).
In light of the strong evidence supporting a connection be-
tween mitochondrial redox homeostasis and mitochondria dy-
namics (3), an attractive hypothesis is that the handling of
mitochondria fragmentation through endogenous or exogenous
antioxidants could be a valid therapeutic strategy to combat PD.
In this frame, superoxide anions, mainly produced during mito-
chondrial oxidative phosphorylation (16), appear to be the most
suitable targets for antioxidant therapies. Superoxide radicals are
considered the ‘primary’ ROS as they can further react with other
molecules to produce more reactive ‘secondary’ ROS, such as hy-
droxyl radicals and peroxynitrites (3). Recently, we have demon-
strated the protective role of the superoxide dismutase enzymes,
SOD1 and SOD2, and of the SOD-mimetic agent M40403 in
paraquat-based cell and fly models of PD (17). In light of these re-
sults, the aim of the present work was to verify whether endoge-
nous and exogenous superoxide dismutating molecules might
rescue the toxic effects induced by PINK1 and Parkin loss in both
cellular and fly models. Our results indicate that boosting either
endogenous or exogenous SOD capability can ameliorate patho-
logically linked phenotypes in vitro and in vivo. Moreover, our re-
sults indicate a more prominent detrimental effect coming from
mitochondrial superoxide. These results support and expand the
field of the potential use of SOD-mimetic compounds as a thera-
peutic strategy in Parkinson’s disease.
Results
PINK1 and Parkinmutagenesis using the CRISPR/Cas9
system
To generate PINK1 and Parkin deficient cells, we used the
CRISPR/Cas9 technology to modify genomic DNA in an
irreversible manner (18). The CRISPR/Cas9 adaptive approach
uses a single guide RNA (sgRNA) to direct the Cas9 nuclease and
specifically generate double strand DNA breaks, resulting in
random insertions and deletions in the specific genomic site,
via error-prone non-homologous end joining repair mecha-
nisms (18). Two different target sequences were designed for
each gene for CRISPR/Cas9 mediated mutagenesis (Fig. 1). These
sequences were cloned in an expression vector containing CD4
as a reporter gene to label transfected cells. As it has been previ-
ously described that endogenous PINK1 can be detected by
western blot in HeLa cells (19), we decided to verify the editing
efficacy of our CRISPR/Cas9 constructs in this cell line. As PINK1
is rapidly degraded in polarized mitochondria (20,21), cells were
exposed to carbonyl cyanide 3-chlorophenyl hydrazone to in-
duce mitochondrial membrane depolarization which promotes
PINK1 stabilization and accumulation on the outer mitochondrial
membrane. Figure 1B and C show PINK1 levels in scramble-
transfected and PINK1-edited cells. The two gRNAs used induced
6266% and 3464% reduction, respectively, in protein levels
compared to control cells. In contrast to PINK1, endogenous
Parkin is not detectable in HeLa cells (22). Hence, we employed
HEK-293T cells that have relatively high levels of endogenous pro-
tein (22,23). Figure 1E and F show that the two gRNAs designed
induced a reduction in Parkin levels by 246 9% and 5161%,
respectively, compared to scramble-transfected samples.
PINK1 and Parkin deficiency induces changes in
mitochondrial redox levels in SH-SY5Y cells
Since PINK1 and Parkin loss has been associated with increased
generation of reactive oxygen species (ROS) and oxidative
stress, we decided to test whether in our experimental condi-
tions we were able to detect any redox changes at the mito-
chondrial and cytosolic level. To this aim we employed SH-
SY5Y cells, rather than HeLa and HEK cells, because of their
neuronal origin, catecholaminergic phenotype and their wide
use in PD field (24). To monitor oxidative stress, a redox sensi-
tive green fluorescent protein (roGFP2) reporter was used. This
protein, which is characterized by the presence of two cysteine
residues able to form a disulfide bond under oxidizing condi-
tions altering its fluorescence properties (25), allows the mea-
surement of cellular redox state in live cells, regardless of the
absolute levels of probe concentration, through ratiometric im-
aging of 405 nm versus 488 nm excitation (25). To discriminate
whether redox state alteration involves different cell compart-
ments, we used two different variants of roGFP2: one was cyto-
solic (cyt-roGFP2), while the other one was specifically targeted
to mitochondria (mt-roGFP2) as previously reported (25). After
calibrating our system, as previously described (17), this tech-
nique was used to assess the cellular redox state in PINK1- and
Parkin-targeted cells. In Figure 2A, representative pseudocolor
ratio pictures of PINK1- and Parkin-deficient cells expressing mt-
roGFP2 are reported. As represented in Figure 2B and C, the loss
of either PINK1 or Parkin protein increased the oxidative state at
the mitochondrial level while the cytosol redox potential re-
mained unaffected.
Superoxide dismutation rescues mitochondrial
redox state alterations in PINK1- and Parkin-deficient
SH-SY5Y cells
To verify the contribution of superoxide radicals to the redox al-
teration observed in our cellular models of PINK1 and Parkin
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deficiency, we analysed the redox state upon loss of PINK1 or
Parkin in previously described SH-SY5Y cells stably overexpress-
ing SOD1 or SOD2 (17) by means of the roGFP2 probe. Since no al-
teration in the cytosolic redox state was observed, we evaluated
the effects of overexpressing SOD1 or SOD2 solely on the mito-
chondrial oxidative state. The results obtained in PINK1-deficient
cells (Fig. 3A) showed that the increased removal of superoxide
radicals was able to reduce the oxidative state at the mitochon-
drial level, with SOD2 generally having a greater effect than SOD1.
Similar results were also obtained in the Parkin-deficient cells. As
shown in Figure 3B, the overexpression of either SOD1 or SOD2
was all able to reduce the mitochondrial oxidative state.
We next analysed the potential of the SOD mimetic com-
pound M40403 to ameliorate PINK1/Parkin-related cell defects.
Encouragingly, the administration of the SOD-mimetic drug
M40403 significantly restored the redox state of both PINK1 and
Parkin-deficient cells (Fig. 3A and B). Overall, these results
demonstrate that loss of PINK1 or Parkin protein leads to
increased oxidative stress in mitochondria, which can be
ameliorated by genetic or pharmacological upregulation of su-
peroxide dismutation. We next sought to determine whether
superoxide dismutation could also provide some improvements
in mitochondria morphology in PINK1/Parkin loss of function
models.
PINK1 and Parkin deficiency leads to changes in
mitochondrial morphology in SH-SY5Y cells
In light of the mitochondrial redox state alteration detected in the
previous experiments and since both mitochondrial ROS produc-
tion and PINK1/Parkin deficiency have been described to induce
mitochondrial fragmentation in several mammalian cell models
(26–31), we next analysed mitochondrial morphology in CRISPR/
Cas9 edited SH-SY5Y cells. Using the CD4 reporter to monitor the
PINK1- and Parkin-targeted editing by anti-CD4 immunofluores-
cence, we evaluated the mitochondrial network in CD4þ cells. As
previously reported, mitochondrial network was scored as tubu-
lar, which is characterized by elongated mitochondria with high
A
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Figure 1. PINK1- and Parkin-editing in HeLa and HEK-293T cells. (A) Schematic representation of the gRNA target sequences in PINK1 gene. Arrows indicate Cas9 DNA
cutting sites. (B) Western blot analysis of PINK1 in HeLa cells transiently expressing scramble, CRISPR-PINK1-A or CRISPR-PINK1-B plasmids. GAPDH signal was used as
loading control. (C) Densitometric analysis of PINK1 levels normalized to GAPDH expressed in percentage. Data are expressed as mean6SEM of three independent ex-
periments. (D) Schematic representation of the gRNA target sequences in parkin gene. Arrows indicate Cas9 DNA cutting sites. (E) Western blot analysis of Parkin in
HEK-293T cells transiently expressing scramble, CRISPR-Parkin-A or CRISPR-Parkin-B plasmids. GAPDH signal was used as loading control. (F) Densitometric analysis
of Parkin levels normalized to GAPDH expressed in percentage. Data are expressed as mean6SEM of three independent experiments.
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interconnectivity, intermediate, which includes a mixture of cir-
cular and short tubular mitochondria, and fragmented, which is
mainly constituted by very small and round mitochondria (17,32)
(Fig. 4A). Importantly, to avoid unintentional bias, mitochondrial
morphology was scored blind to the experimental conditions.
Consistent with the aforementioned works, in comparison to
control-transfected cells, PINK1 deficiency led to alterations in mi-
tochondrial morphology. Specifically, as shown in Figure 4B, a sig-
nificant decrease in the percentage of mitochondria with tubular
morphology was observed with a concomitant accumulation of
organelles with intermediate and fragmented morphology. As ex-
pected, the loss of Parkin in our cell model also strongly decreased
the number of tubular mitochondria while increasing the amount
of intermediate and fragmented organelles (Fig. 4C), in agreement
with previously published results (31). For all conditions, a selec-
tion of representative images are shown in Supplementary
Material, Figures S1 and S2.
Superoxide dismutation induces rescue of
mitochondrial morphological alterations in PINK1- and
Parkin-deficient SH-SY5Y cells
The protective effects of superoxide dismutation were then
analysed in SOD1- or SOD2-overexpressing SH-SY5Y cells. As re-
ported in Figure 5a, both the enzymes were able to partially res-
cue the mitochondrial alterations induced by loss of PINK1
protein, but the effects were much more pronounced by the
overexpression of SOD2. While SOD1 partially reduced mito-
chondria fragmentation by increasing the number of cells
with an intermediate mitochondrial morphology, in the
presence of SOD2 the reduction of fragmented organelles
correlated with a restoring of tubular mitochondria. Similar to
PINK1-edited cells, the mitochondria morphological impairment
in Parkin-targeted SH-SY5Y cells was significantly rescued by
the overexpression of either SOD1 or SOD2. In both conditions,
the reduction of fragmented organelles correlated with a restor-
ing of tubular mitochondria. Representative images are shown
in Supplementary Material, Figures S1 and S2.
Having verified the beneficial effects of SOD enzymes we
then evaluated the potential protective role of the M40403 SOD-
mimetic compound. Interestingly, in PINK1 deficient cells, we
observed a protective trend of M40403 against mitochondria
fragmentation with an increase in both the intermediate and
the tubular states, although this did not reach statistical signifi-
cance in these assays (Fig. 5A). However, the effects were
greater in Parkin deficient cells: the treatment with M40403 sig-
nificantly reduced the number of fragmented mitochondria
while restoring tubular mitochondria (Fig. 5B).
Pink1 and parkinmutant Drosophila brains display
elevated ROS levels
Having demonstrated the potential for SODs to reverse pheno-
types associated with loss of PINK1 and Parkin proteins, to
A B
C
Figure 2. Analysis of the redox state in PINK1- and Parkin-edited SH-SY5Y cells—(A) Representative pseudocolor ratiometric images of scramble, CRISPR-PINK1 and
CRISPR-Parkin transfected SH-SY5Y cells expressing the mito-roGFP probe. The 405/488 ratio was coded on a spectral color scale ranging from black (fully reduced) to
red (fully oxidized), with the limits set after calibration. CD4 positive cells were identified after incubation with Alexa FluorVR 647 anti-human CD4 Antibody (arrowheads
in the figure). Scale bar: 30 mm. (B) Mitochondrial oxidation state of 60–70 CD4 positive cells from four independent experiments was measured using the mito-roGFP
probe. (C) Cytosolic oxidation state of 40–50 CD4 positive cells from three independent experiments was measured using the cyto-roGFP probe. Fluorescence ratios
(405/488) were calculated in scramble, CRISPR-PINK1 or CRISPR-Parkin transfected SH-SY5Y cells and normalized with respect with the ratios corresponding to the
100% reduced and oxidized state. Data are reported as mean6SEM and statistical significance was determined by One way ANOVA and Dunnett’s post-hoc test.
###P<0.001 compared to scramble.
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extend our analysis in vivo we turned to well characterised
Drosophila models of PINK1/parkin deficiency. Drosophila Pink1
and parkin mutants display a number of characteristic pheno-
types analogous to the disease condition including locomotor
deficits and neurodegeneration (33,34). To determine the level
of oxidative stress we used established methods to analyse cy-
tosolic and mitochondrial ROS in Pink1 and parkin mutants
brains. Using the H2DCFDA dye we found no significant change
in cytosolic ROS in Pink1 or parkin mutants (Fig. 6A and B). In
contrast, the mito-roGFP2-Orp1 mitochondrial ROS reporter re-
vealed increased mitochondrial ROS in both Pink1 and parkin
mutants (Fig. 6A and C).
Superoxide dismutation-induced rescue in Pink1 and
parkin knockout Drosophilamodels
To assess the contribution of ROS to Pink1 and parkin mutant
phenotypes, these mutants were genetically combined with
transgenic lines expressing Drosophila Sod (homologous to mam-
malian SOD1) or Sod2 (homologous to mammalian SOD2) and
the ubiquitous da-GAL4 driver, and assayed for locomotor abil-
ity (via negative geotaxis or climbing). In Pink1 mutants Sod
expression did not rescue climbing ability while Sod2 substan-
tially suppressed the climbing defect (Fig. 7A). Similarly, in par-
kin mutants expression of Sod2 substantially rescued climbing
ability; however, here Sod expression also modestly improved
locomotion (Fig. 7B).
We next wanted to address whether the M40403 SOD-
mimetic could provide beneficial effects in vivo. Pink1 and parkin
mutant and control flies were raised on food dosed with varying
concentrations of M40403 and climbing ability was again tested.
In parallel, animals of the same genotypes were raised on stan-
dard non-drug treated food for comparison. For both Pink1 and
parkin mutants M40403 treatment significantly improved climb-
ing ability (Fig. 8). The rescue was largely in a dose dependent
manner within the range analysed. However, while in parkin
mutants a modest rescue was seen with the lowest dose
(0.01 mM), which was not significant in Pink1 mutants, the
beneficial effects were lost at the highest dose (0.1 mM), which
afforded the best rescue in Pink1 mutants. Taken together these
results indicate that increasing endogenous or exogenous SOD
activity can be beneficial in two in vivo models of PD.
Discussion
Strong evidence exists linking oxidative stress and mitochon-
dria dysfunction to both familial and sporadic PD cases (1).
Accumulating indications also support that elevated ROS levels
and abnormalities in mitochondria morphology are intercon-
nected (3). As fragmented mitochondria are often observed in
human pathological conditions, including PD (35), the reversal
of such a morphological phenotype, through the modulation of
endogenous antioxidant levels or by the application of exoge-
nous antioxidants, might represent a valid therapeutic strategy.
Nevertheless, clinical trials on PD patients based on antioxidant
drugs have yielded mixed results (36). A possible explanation is
that most of the tested molecules do not target the primary
cause of the oxidative stress, i.e. excessive superoxide anion
production, but rather the downstream effects. In cells, super-
oxide anions are mainly formed in mitochondria during oxida-
tive ATP production, when a small leakage of electrons from the
electron transport chain can directly react with oxygen to pro-
duce superoxide radicals (16). Accordingly, a treatment strategy
for oxidative stress is likely to be more effective if it targets the
origin of ROS generation.
In the present work we analysed the therapeutic potential of
antioxidant molecules capable of decreasing superoxide radi-
cals in two genetic models of PD, based on loss of PINK1 or
Parkin function. We first established that the loss of PINK1 or
Parkin protein in human neuroblastoma SH-SY5Y cells induces
an increase in the mitochondrial oxidative state while the cyto-
solic redox state remains unaltered. Moreover, in both PINK1-
and Parkin-deficient cells we observed a strong increase in the
number of fragmented mitochondria, in comparison to wild-
type cells. Interestingly, the overexpression of either SOD1 or
SOD2 was able to prevent alteration in the redox state of mito-
chondria and to partially rescue the mitochondria fragmenta-
tion, albeit with more pronounced effects seen by SOD2
overexpression. Having demonstrated in vitro the beneficial ef-
fects of the superoxide dismutating endogenous enzymes, we
then moved to a relevant in vivo model. Consistent with the in
vitro findings, overexpression of Sod2, and to a lesser extent
Sod, ameliorated locomotion defects in Pink1 or parkin mutants.
Consistent with our results, it has been previously reported
that in SH-SY5Y cells PINK1 gene silencing increases the
level of mitochondrial superoxide which, in turn, promotes
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Figure 3. Effects of superoxide dismutation in the mitochondrial redox state of
PINK1- and Parkin-edited SH-SY5Y cells—Wild-type, SOD1- or SOD2-overex-
pressing SH-SY5Y cells were transfected with scramble, CRISPR-PINK1- or
CRISPR-Parkin vectors and treated with M40403 when indicated. Fluorescent ra-
tios (405/488) were normalized with respect with the ratios corresponding to the
100% reduced and oxidized state. Data from three independent experiments are
reported as mean6SEM and statistical significance was determined by One-
way ANOVA with Dunnett’s post-hoc analysis. #P<0.05, ##P<0.01 and ###P<0.001
compared with scramble transfected cells and *P<0.05, **P<0.01 and ***P<0.001
as indicated in the graph.
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mitochondrial fragmentation (27), and superoxide radicals have
been proposed as essential mediators in triggering fragmenta-
tion of the mitochondrial network (27). In this frame, the protec-
tive effects observed by overexpressing SOD1, in terms of
mitochondrial morphology and redox state, could be explained
considering that, besides the cytosolic localization, the protein
is also found in the mitochondrial intermembrane space.
In an important extension to the genetic manipulation of su-
peroxide dismutation, we also showed that treatment with the
SOD-mimetic compound M40403 reversed several effects of loss
of PINK1/Parkin protein. In both PINK1- and Parkin-deficient cell
models, M40403 preserved the redox state of these organelles
and inhibited mitochondria fragmentation, with effects that
were more pronounced in Parkin deficient cells. Similarly, we
also observed beneficial effects from the systemic administra-
tion of M40403 in Pink1 and parkin mutant flies. Interestingly,
the dose-response to M40403 differed slightly between the two
mutant models. In Pink1 mutants increasing M40403 concentra-
tion provided an increasing benefit across the concentrations
tested, becoming substantial in the highest dose. However, in
parkin mutants, although there was a dose-dependent improve-
ment in locomotion across low and mid-range concentrations,
which was lost at the highest dose, the magnitude was appre-
ciably less than in Pink1 mutants. The reason for the
slightly weaker rescue is not currently clear but in our experi-
ence parkin mutants display slightly stronger phenotypes than
Pink1 mutants, which is evident in the generally slightly poorer
climbing performance seen here. Nevertheless, these results
demonstrate that abrogating the damaging effects of superox-
ide is beneficial in these in vivo models of Parkinson’s disease.
While it is currently unclear exactly how loss of PINK1 or
Parkin leads to the elevated oxidative stress, they are consid-
ered to play a central role in mitochondrial quality control,
promoting mitophagy and other related processes [reviewed in
(37,38)]. A breakdown in quality control processes will lead to
accumulated dysfunctional mitochondria which will inevitably
produce high levels of ROS. This provides a clear molecular ba-
sis for elevated oxidative stress in PINK1/parkin linked PD cases,
but oxidative stress is also a feature of idiopathic PD pathology
(39). In dopaminergic neurons oxidative stress has been sug-
gested to arise at least in part from the oxidation of dopamine,
generating both ROS and very reactive electron-deficient dopa-
mine-quinones (DAQs) (40,41), which can conjugate a wide vari-
ety of macromolecules. Notably, Parkin as well as other PD-
related factors such as DJ-1 and alpha-synuclein have been
found to be modified by DAQs (42–44). Interestingly, SOD2 has
also been described to be modified by DAQ affecting its activity
and causing aggregation (45). Reducing this defence mechanism
will inevitably lead to increases in oxidative stress. Moreover,
very recently copper-deficient SOD1 aggregates as well as re-
duced enzymatic activity of SOD1 have been observed in vulner-
able brain regions of idiopathic PD patients (46). Since SOD1
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requires copper for catalysis, it is also notable that levels of cop-
per and Copper transporter protein 1 are significantly reduced
in remaining substantia nigra and locus coeruleus neurons of
PD patients (47), suggesting that a reduction in cellular copper
may affect the ability of vulnerable neurons to protect against
oxidative stress.
In conclusion, all of this evidence supports a fundamental role
for ROS derived oxidative stress as a contributing factor across
the spectrum of PD. While further work in needed to understand
the nature of detrimental effects of superoxide production and
how this leads to neuronal cell death, our results presented here
support the further exploration of endogenous and exogenous
SOD-related molecules as a therapeutic strategy against PD.
Materials and Methods
Antibodies
The following antibodies were used: rabbit monoclonal anti-
PINK1 antibody (D8G3, Cell Signalling Technology), mouse
monoclonal anti-parkin antibody (sc-32282, Santa Cruz
Biotechnology), rabbit Polyclonal anti-GAPDH antibody (Origene),
anti-mouse and anti-rabbit IgG peroxidase antibodies (Sigma),
Alexa FluorVR 488 anti-human CD4 antibody (clone OKT4,
BioLegend) and Alexa FluorVR 647 anti-human CD4 antibody (clone
OKT4, BioLegend).
Guide RNAs cloning into the CRISPR/Cas9 vector
Endogenous PINK1 and parkin genes have been edited by means
of the CRISPR/Cas9 system. All guide RNA candidate target se-
quences (gRNAs) contain the NGG sequence at the 3’ end
(PAM domain). The gRNAs were chosen to exhibit low off-target
activity in genic regions of the human genome, according to
CRISPR RGEN online tools (http://rgenome.net/cas-offinder/).
The gRNAs were cloned in an expression vector containing
a Cas9 nuclease expression cassette and a CD4 reporter
[GeneArtVR CRISPR Nuclease (CD4 Enrichment) Vector Kit, Life
Technologies] according to manufacturer’s instructions.
Positive colonies were confirmed by DNA sequencing. For each
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Figure 5. Effects of superoxide dismutation in mitochondrial morphology of PINK1- and Parkin-edited SH-SY5Y cells—Wild-type, SOD1- or SOD2-overexpressing SH-
SY5Y cells were co-transfected with mitoRFP—and (A) CRISPR-PINK1-vectors or (B) CRISPR-Parkin-vectors and treated with M40403 when indicated. Mitochondrial net-
work was scored as tubular, intermediate and fragmented. The percentage of cells with a specific mitochondrial network was determined as a percentage of the total
number of CD4 positive cells counted. At least 35 CD4 positive cells were analysed per experiment. Data are expressed as mean6SEM of at least three independent ex-
periments. Statistical significance was assessed by One-way ANOVA with Dunnett’s post-hoc analysis. #P<0.05, ##P<0.01 and ###P<0.001 compared with scramble
transfected cells and *P<0.05, **P<0.01 and ***P<0.001 as indicated in the graphs.
1624 | Human Molecular Genetics, 2018, Vol. 27, No. 9
Downloaded from https://academic.oup.com/hmg/article-abstract/27/9/1618/4908668
by University of Cambridge user
on 04 July 2018
gene of interest two gRNAs were selected to introduce double
strand break within the genomic DNA. A scramble sequence
was used as negative control. The following pairs of primers
were used:
1) PINK1-A top50-CCGCTTCTTCCGCCAGTCGGGTTTT-30;
PINK1-A bottom50-CCGACTGGCGGAAGAAGCGGCGGTG-
30;
2) PINK1-B top50-CGTAATTCACATTGGAGCAGGTTTT-30;
PINK1-B bottom50-CTGCTCCAATGTGAATTACGCGGTG-30;
3) PARKIN-A top50-CAGTTGCGTGTGATTTTCGCGTTTT-30;
PARKIN-A bottom50-GCGAAAATCACACGCAACTGCGGT
G-30
4) PARKIN-B top50-TCCACCCGAGTCAAGCTCTGGTTTT-30
PARKIN-B bottom50-CAGAGCTTGACTCGGGTGGACGGTG-
30
5) Scramble-top50-GCACTACCAGAGCTAACTCAGTTTT-30
Scramble-bottom50-TGAGTTAGCTCTGGTAGTGCCGGTG-
30
Cell culture and drug treatments
Human embryonic kidney cells (HEK293T, ATCCVR ) and human
adenocarcinoma cells (HeLa, ATCCVR ) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM, Thermo Fisher)
supplemented with 10% fetal bovine serum (Thermo Fisher) at
37C and 5% CO2. To assess PINK1 protein levels, HeLa cells
were treated with 4 mM MG132 (Sigma-Aldrich) and with 10 mM
carbonyl cyanide 3-chlorophenylhydrazone (CCCP, Sigma-
Aldrich) for 24 h and 4 h, respectively, at 37C before cell lysis.
Human neuroblastoma SH-SY5Y cells (IST, Genova, Italy) were
cultured in a 1:1 mixture of Ham’s F12 and Dulbecco Modified
Eagle Medium (Life Technologies) supplemented with 10% fetal
bovine serum, in a 5% CO2 humidified incubator at 37C.
Previously described SOD1 and SOD2 stably overexpressing SH-
SY5Y cells were used (17). When required, SH-SY5Y cells were
treated with 10 mM SOD mimetic drug M40403 for 24 h at 37C.
Isolation of CD4 positive cells
Twenty-four hours after seeding in 10 cm dishes, HEK293T and
HeLa cells were transfected with 10 lg of DNA using
A
B C
Figure 6. Analysis of redox state in Pink1 and parkin deficient flies. (A) Pseudocolour representative images of adult Drosophila brains imaging cytosolic (H2DCFDA) or mi-
tochondrial (mt-roGFP2-Orp1) ROS reporters in control (w1118), park25 or Pink1B9 adult brains. Scale bars¼100 mm. (B) Quantification of cytosolic (H2DCFDA) ROS normal-
ised to control; control n¼10, park25 n¼9 and Pink1B9 n¼9. (C) Quantification of mitochondrial (mt-roGFP2-Orp1) ROS normalised to control; control n¼16, park25 n¼20
and Pink1B9 n¼16. Charts show mean6SD. Statistical analysis used Kruskal–Wallis with Dunn’s multiple comparisons test (*P<0.05; ns, non-significant).
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polyethylenimine (PEI, Polysciences) as transfection vehicle
with a PEI to DNA w/w ratio of 4/1 and 2/1, respectively. To in-
crease the number of transfected cells in the cell cultures, CD4
positive cells were isolated before the evaluation of PINK1 and
parkin protein levels. For this purpose, 72 h after seeding, cells
were subjected to CD4 isolation with the DynabeadsVR CD4
Positive Isolation Kit (Life Technologies), according to manufac-
turer’s instructions. Isolated CD4 positive cells were then plated
into six well plates for western blot analysis.
Western blotting
To assess PINK1 and Parkin protein levels, transfected HEK293T
and HeLa cells were lysed in 20 mM Tris–HCl buffer, pH 7.5, con-
taining 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 2.5 mM so-
dium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM
Na3VO4, protease inhibitor cocktail (Sigma) and kept on ice for
30 min. Clarified lysates were obtained by centrifugation at
17 500g for 15 min at 4C. The detergent-soluble supernatant
fractions were quantified by BCA assay (Pierce Biotechnology).
Proteins (50 mg) were separated by SDS-PAGE, transferred on
PVDF membranes (Immobilion, Millipore) and subjected to
western blot analysis using appropriate primary and secondary
antibodies. Immunoreactive proteins were visualized using
enhanced chemiluminescence (GE Healthcare). Densitometry
was performed by using Image J Software and endogenous
GAPDH protein was used as loading control.
Mitochondrial morphology analysis
Wild-type, SOD1 or SOD2 overexpressing SH-SY5Y cells were
plated on fibronectin-coated coverslips in 24-well plates (120 000
cells/well) and 24 h later co-transfected with 0.25 mg of mito-RFP
vector (a gift from Prof. Luca Scorrano, University of Padua, Italy)
and 0.75 mg of CRISPR/Cas9 vector using Lipofectamine (Life
Technologies) as transfection reagent according to manufacturer’s
instructions. After fixation with 4% paraformaldehyde, cells were
stained using the anti-CD4 antibody conjugated to Alexa FluorVR
488 fluorochrome. Nuclei were counterstained using 0.16 lm
Hoechst 33258 (Life technologies). Images were acquired using a
Leica 5000B epifluorescent microscope with the 100 oil objective
(numeric aperture: 1.30). Data analysis was performed on CD4 pos-
itive cells, in a blind manner and reported as percentage of cells
with tubular, intermediate or fragmented morphology.
Cellular roGFP analysis
Wild-type, SOD1 or SOD2 overexpressing SH-SY5Y cells were
plated on fibronectin-coated plates (m-Slide 8 well, Ibidi) at a
density of 70 000 cells/well. The next day cells were co-
transfected with 100 ng of cyto- or mito-roGFP and 600 ng of
CRISPR-Cas9 vector using Lipofectamine (Life Technologies) ac-
cording to manufacturer’s instruction. To identify CD4 positive
cells, 48 h after transfection cells were incubated with 1:200
Alexa FluorVR 647 anti-human CD4 antibody in phenol-red free
media. Images were collected with a Leica SP5 confocal micro-
scope with 40 objective (oil immersion, numeric aperture:
1.25–0.75). Fluorescence was collected between 500 and 530 nm
using 405 and 488 nm as excitation wavelengths. Prior the ex-
periments, cyto- and mito-roGFP probes were calibrated in pres-
ence of 1 mM H2O2 (100% oxidized state) and 4 mM DTT (0%
oxidized state). To avoid photobleaching and/or laser-induced
oxidation during calibration, images were acquired every 2 min
using a wide pinhole and a fast scanning (512 512 resolution).
Fluorescence settings were kept constant across experiments
and conditions. Raw data were exported to ImageJ software
(http://rsb.info.nih.gov/ij/). Each cells in the field was selected as
region of interest (ROI) and the mean intensity of each ROI was
then measured after appropriate background correction. Three
to four independent experiments were performed and in each
one, a total number of 20–30 CD4 positive cells per condition
were quantified and analysed.
Drosophila strains and culture
Flies were raised under standard conditions at 25C on food
consisting of agar, cornmeal, molasses and yeast. Pink1B9 mu-
tants were a kind gift from J Chung (34), and the UAS-mito-
roGFP2-Orp1 was provided by A. Sanz (48). park25 mutants have
been described previously (33). The following strains were ob-
tained from the Bloomington Drosophila Stock Center: da-GAL4
(#5460), UAS-Sod (#33605) and UAS-Sod2 (#24494).
In vivo ROS measurement
In Drosophila, ROS analysis was performed as previously de-
scribed (49). Dichlorofluorescein (H2DCFDA; Sigma, D399) was
A
B
Figure 7. Analysis of Sod and Sod2 expression in Pink1/parkin mutant locomotor
assays. Climbing assay of (A) Pink1 and (B) parkin mutant flies upon ubiquitous
(da-GAL4 driver) transgenic expression of Sod or Sod2. Charts show mean and
95% CI, n>100 animals. Statistical analysis used Kruskal–Wallis with Dunn’s
multiple comparisons test (*P<0.05, ***P<0.001, ****P<0.0001; ns, non-
significant).
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used to measure total cytosolic ROS levels in 3–5 days old
adults. Brains were dissected in PBS then incubated in 30 lM
H2DCFDA for 10 min before being washed three times with PBS
and imaged immediately. Mitochondrial ROS imaging was per-
formed using mito-roGFP2-Orp1 reporter lines, 3–5 days old
adult fly brains were dissected in PBS and imaged by excitation
at 488 nm (reduced) or 405 nm (oxidized), with emission re-
corded at 510 nm. Images were acquired using an LSM880 con-
focal microscope (Zeiss) equipped with a 20 0.8 NA. The
maximum intensity of projected z-stacks from imaged brains
was quantified using ImageJ.
Locomotion assay
The mobility of flies from each genotype was assessed using a
counter-current apparatus in a negative geotaxis climbing as-
say. One to two-day-old flies were placed in an empty plastic
vial (2.5 cm diameter), gently tapped to the bottom, and the
number of flies crossing a line at 8 cm height within a time pe-
riod of 10 s was scored. Each animal was tested five times. The
number of male flies tested per genotype was n> 150. To inves-
tigate whether the M40403 compound could rescue the strong
phenotype of Pink1B9 and park25 mutants, the treatment was
performed throughout development (from egg-laying to adult
eclosion) through the addition of varying concentrations of
M40403 during food preparation.
Statistical analysis
Cell data were analysed on Prism by one-way ANOVA with the
Dunnett’s post-hoc test. Climbing data were analysed by
Kruskal–Wallis non-parametric test with Dunn’s post-hoc test
for multiple comparisons. The effect of M40403 on climbing was
analysed by two-way ANOVA with Dunnett’s post-hoc test for
multiple comparisons. P< 0.05 was considered significant.
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